ATYR
Atyr Pharma Inc (ATYR)
Healthcare • NASDAQ • $0.95+2.66%
- Symbol
- ATYR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.95
- Daily Change
- +2.66%
- Market Cap
- $92.79M
- Trailing P/E
- N/A
- Forward P/E
- -2.36
- 52W High
- $7.29
- 52W Low
- $0.64
- Analyst Target
- $4.36
- Dividend Yield
- N/A
- Beta
- 0.66
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a doma…
Company websiteResearch ATYR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.